Pathophysiology of ischaemic heart disease by Pocock, MO, Dorrell, L, Cicconi, P

First-in-human randomized study to assess the safety and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine based on chimpanzee-adenovirus-155 viral vec... by Cicconi, P, Jones, C, Sarkar, E, Silva Reyes, L, Klenerman, P, De Lara, C, Hutchings, C, Moris, P, Janssens, M, Fissette, L, Picciolato, M, Leach, A, Leach, A, Gonzalez Lopez, A, Dieussaert, I, Snape, M

A novel vaccine strategy employing serologically different chimpanzee adenoviral vectors for the prevention of HIV-1 and HCV coinfection by Hartnell, F, Brown, A, Capone, S, Kopycinski, J, Bliss, C, Makvandi-Nejad, S, Swadling, L, Ghaffari, E, Cicconi, P, Del Sorbo, M, Sbrocchi, R, Esposito, I, Vassilev, V, Marriott, P, Gardiner, C, Bannan, C, Bergin, C, Hoffmann, M, Turner, B, Nicosia, A, Folgori, A, Hanke, T, Barnes, E, Dorrell, L, PEACHI Consortium

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four random... by Voysey, M, Costa Clemens, SA, Madhi, SA, Folegatti, PM, Aley, PK, Angus, B, Bibi, S, Cicconi, P, Clutterbuck, EA, Dold, C, Emary, KRW, Ewer, KJ, Flaxman, A, Feng, S, Green, CM, Greenland, M, Jenkin, D, Joe, CCD, Kerridge, S, Marchevsky, NG, Minassian, AM, Mujadidi, Y, Phillips, DJ, Plested, E, Ramasamy, M, Ritchie, AJ, Robinson, H, Song, R, Snape, MD, Douglas, AD, Hill, AVS, Lambe, T, Gilbert, SC, Pollard, AJ

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial by Emary, KRW, Golubchik, T, Aley, PK, Angus, B, Bibi, S, Bonsall, D, Cicconi, P, Clutterbuck, EA, Dold, C, Douglas, AD, Ewer, KJ, Flaxman, AL, Feng, S, Folegatti, PM, Fuskova, M, Green, CM, Green, CA, Greenland, M, Jenkin, D, Kerridge, S, Marchevsky, NG, Minassian, AM, Mujadidi, YF, Phillips, DJ, Plested, E, Robinson, H, Song, R, Snape, MD, Hill, AVS, Lambe, T, Gilbert, SC, Voysey, M, Ramasamy, MN, Pollard, AJ, Et al.

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) by Flaxman, A, Marchevsky, NG, Jenkin, D, Aboagye, J, Aley, PK, Angus, B, Belij-Rammerstorfer, S, Bibi, S, Bittaye, M, Cappuccini, F, Cicconi, P, Clutterbuck, EA, Davies, S, Dejnirattisai, W, Dold, C, Ewer, KJ, Folegatti, PM, Fowler, J, Hill, AVS, Kerridge, S, Minassian, AM, Mongkolsapaya, J, Mujadidi, YF, Plested, E, Ramasamy, MN, Robinson, H, Sanders, H, Sheehan, E, Smith, H, Snape, MD, Song, R, Woods, D, Screaton, G, Gilbert, SC, Voysey, M, Pollard, AJ, Lambe, T

MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans by Esposito, I, Cicconi, P, D'Alise, AM, Brown, A, Esposito, M, Swadling, L, Holst, PJ, Bassi, MR, Stornaiuolo, M, Mori, F, Vassilev, V, Li, W, Donnison, T, Gentile, C, Turner, B, von Delft, A, Del Sorbo, M, Barra, F, Contino, AM, Abbate, A, Novellino, E, Thomsen, AR, Christensen, JP, Lahm, A, Grazioli, F, Ammendola, V, Siani, L, Colloca, S, Klenerman, P, Nicosia, A, Dorrell, L, Folgori, A, Capone, S, Barnes, E

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK by Voysey, M, Clemens, SAC, Madhi, SA, Weckx, LY, Folegatti, PM, Aley, PK, Angus, B, Baillie, VL, Barnabas, SL, Bhorat, QE, Bibi, S, Briner, C, Cicconi, P, Collins, AM, Colin-Jones, R, Cutland, CL, Darton, TC, Dheda, K, Duncan, CJA, Emary, KRW, Ewer, KJ, Fairlie, L, Faust, SN, Feng, S, Ferreira, DM, Finn, A, Goodman, AL, Green, CM, Green, CA, Heath, PT, Hill, C, Hill, H, Hirsch, I, Hodgson, SHC, Izu, A, Jackson, S, Jenkin, D, Joe, CCD, Kerridge, S, Koen, A, Kwatra, G, Lazarus, R, Lawrie, AM, Lelliott, A, Libri, V, Lillie, PJ, Mallory, R, Mendes, AVA, Milan, EP, Minassian, AM, Lambe, T, Pollard, AJ

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial by Ramasamy, MN, Minassian, AM, Ewer, KJ, Flaxman, AL, Folegatti, PM, Owens, DR, Voysey, M, Aley, PK, Angus, B, Babbage, G, Belij-Rammerstorfer, S, Berry, L, Bibi, S, Bittaye, M, Cathie, K, Chappell, H, Charlton, S, Cicconi, P, Clutterbuck, EA, Colin-Jones, R, Dold, C, Emary, KRW, Fedosyuk, S, Fuskova, M, Gbesemete, D, Green, C, Hallis, B, Hou, MM, Jenkin, D, Joe, CCD, Kelly, EJ, Kerridge, S, Lawrie, AM, Lelliott, A, Lwin, MN, Makinson, R, Marchevsky, NG, Mujadidi, Y, Munro, APS, Pacurar, M, Plested, E, Rand, J, Rawlinson, T, Rhead, S, Robinson, H, Ritchie, AJ, Ross-Russell, AL, Saich, S, Singh, N, Pollard, AJ, Oxford COVID Vaccine Trial Group

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire. by Swanson, PA, Padilla, M, Hoyland, W, McGlinchey, K, Fields, PA, Bibi, S, Faust, SN, McDermott, AB, Snape, MD, Voysey, M, Lambe, T, Pollard, AJ, Durham, NM, Kelly, EJ, Adlou, S, Aley, PK, Angus, B, Anslow, R, Baker, P, Bansal, H, Beveridge, A, Bridges-Webb, A, Ching, S, Cicconi, P, Clutterbuck, EA, Collins, AM, Darton, TC, Demissie, T, Dinesh, T, Douglas, AD, Duncan, CJA, Ewer, KJ, Felle, S, Ferreira, DM, Folegatti, PM, Fuskova, M, Gaudinski, M, Gilbert, SC, Goodman, AL, Gordon, I, Green, CA, Harbolick, E, Hayes, S, Hill, AVS, Hill, H, Jenkin, D, Jepson, BM, Kasanyinga, M, Libri, V, Lillie, PJ, McGregor, AC